Loading question session…
9 questions
Which pharmacokinetic process primarily determines the duration of action of a drug with a high volume of distribution?
A patient taking Drug A, a potent CYP3A4 inhibitor, begins treatment with Drug B, primarily metabolized by CYP3A4. What is the most likely outcome of this drug interaction?
Which mechanism best explains an idiosyncratic adverse drug reaction?
How does a drug with zero-order kinetics differ from one with first-order kinetics in terms of plasma concentration changes?
Why might co-administration of two drugs both highly bound to plasma albumin result in increased free concentration of one drug?
What is the primary reason for a drug to exhibit a significant first-pass effect?
A drug that inhibits the cytochrome P450 system can decrease the metabolism of co-administered drugs metabolized by the same enzymes, potentially increasing their toxicity.
All adverse drug reactions are dose-dependent and predictable based on the drug's primary pharmacology.
The bioavailability of an orally administered drug is always less than 100% due to incomplete absorption and first-pass metabolism.